Invetx, a US-based developer of protein-based therapeutics for animal health backed by strategic investors AbCellera Biologics and WuXi Biologics, has added $10.25m to its series A round, bringing the total to $25.5m.
New investors include investment firms Casdin Capital and Tekla Capital Management, joining existing lead investor Anterra Capital and the corporate venturing units.
In February, Invetx raised $15m led by Anterra Capital, a growth equity fund backed by banking firm Rabobank and investment and financial services firm Fidelity, that had been Invetx’s founding investor.
Invetx is looking to harness protein-based therapeutics and vaccines for use by veterinarians, both on pets and on livestock. It is targeting cancer and diabetes in addition to pain and allergies.
The startup has formed a partnership with WuXi Biologics that will involve it accessing the corporate’s manufacturing capabilities, in addition to an animal health collaboration with antibody discovery services provider AbCellera.
Solebury Capital was financial adviser to Invetx.
